Questions? Feedback? powered by Olark live chat software
All Site

A new partnership with Polyplus Transfection SA

We are very pleased to announce that Polyplus-transfection® SA, has trusted In Vitro Technologies as their new exclusive distributor in Australia and New Zealand.
Located close to the University of Strasbourg in France, Polyplus-transfection® SA is a biotechnology company that develops and sells innovative, high efficiency transfection reagents for the delivery of nucleic acids in research, bioproduction and therapeutics.

06.08.2018

The ATCC Toxicology Portfolio

ATCC's toxicological tools can also be used to identify responses to environmental insults or to screen pharmaceutical compounds. These cells are applicable for bench work and large-scale screening and are fully characterized and  functionally tested.

23.07.2018

What’s news from ATCC?

ATCC has updated the White Paper Synthetic Nucleic Acids for the Development and Evaluation of In Vitro Diagnostic Devices Designed to Detect Dengue, Chikungunya, and Zika White Paper.

18.06.2018

Eradicate Cancer Travel Grant Winners

To support Australian and New Zealand research in the fight against cancer, In Vitro Technologies offered 5 Travel Grants to Australian and New Zealand researchers to attend the Eradicate Cancer Conference in Melbourne in March 2018. And the winners are...

26.02.2018

Betting Twelve Billion Dollars on Cellular Immunotherapy

In the latest vote of confidence that cellular immunotherapy is going to live up to its potential for transforming the way cancer is treated, this week Gilead Sciences purchased Kite Pharma, a leader in the development of chimeric antigen receptor (CAR) T cells, for $11.9 billion dollars.

05.09.2017
Total: 54 posts